image: Professor of surgery at Pitt and UPMC trauma surgeon. view more
Credit: UPMC
PITTSBURGH, Oct. 5, 2020 - Severely injured trauma patients who received a blood-clotting drug before arriving at the hospital had a better chance of surviving than those who didn't, according to new research from the University of Pittsburgh School of Medicine. The results will be reported at the American College of Surgeons Clinical Congress 2020 and published in JAMA Surgery.
The multi-center trial, which took place over four years in Pennsylvania, Texas, Utah and Arizona, was designed to determine whether giving tranexamic acid, a blood-clotting agent, to trauma patients before they arrived at the hospital improved patients' chance of survival. Over the trial period, researchers found that while the drug is safe, it did not significantly reduce 30-day mortality in the majority of patients at risk of hemorrhage following their injuries.
However, "in certain subgroups who got the drug very early--within the first hour--or who had severe shock with a blood pressure less than 70 when the paramedics arrived, there was an improvement in survival," said lead author, Francis X. Guyette, M.D., associate professor of emergency medicine at Pitt and UPMC emergency physician.
The 903 participants in the study were enrolled from emergency calls where patients were at risk of bleeding from trauma. Half got the tranexamic acid treatment, and half got a placebo of saline.
When paramedics arrive at a scene, it's hard to know the full extent of a patient's injuries, making it difficult to determine the level of trauma they've experienced, so the study used simple measurements to enroll patients in the trial.
"The prehospital environment is very unknown," said senior author Jason Sperry, M.D., professor of surgery at Pitt and UPMC trauma surgeon. "All you have is some vital signs and you know they have been injured. Tranexamic acid was given to just about everybody if they had either a high heart rate or low blood pressure."
Tranexamic acid is commonly used in cardiac surgery to help stop bleeding, but previous studies have suggested that the drug may pose risks--including blood clots and strokes--to patients suffering from severe injuries. However, among the severely injured patients in this study who received the drug, none had more risk of these side effects than those who didn't receive the drug. This result suggests tranexamic acid may be safer and more beneficial to trauma patients than originally thought.
Since tranexamic acid is delivered through an IV, it's easy to stock in emergency vehicles. It's also affordable, so paramedics are less likely to ration it for the patients who they suspect have the worst injuries.
"Given that tranexamic acid is safe and has benefit in these subgroups of patients, if we can give it early and give it to all patients with severe injury in the field, we should," said Guyette. "Even though it benefits a few percent of trauma patients, that works out to thousands of patients per year whose lives could be saved."
Guyette and Sperry hope that their findings will be used to modify guidelines for paramedics.
###
Additional authors on this research are Joshua B. Brown, M.D., M.Sc., Mazen S. Zenati, M.D., Ph.D., Barbara J. Early-Young, B.S.N., and Peter W. Adams, B.S., all of Pitt; Brian J. Eastridge, M.D., of the University of Texas Health San Antonio; Raminder Nirula, M.D., M.P.H., of the University of Utah; Gary A. Vercruysse, M.D., of the University of Michigan; Terence O'Keeffe, M.D., of the Medical College of Georgia at Augusta University; and Bellal A. Joseph, M.D., of the University of Arizona.
This research was funded by U.S. Army Medical Research and Materiel Command grant W81XWH 13-2-0080.
To read this release online or share it, visit https://www.upmc.com/media/news/100520-Tranexamic-Acid [when embargo lifts].
About the University of Pittsburgh School of Medicine
As one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region's economy. For more information about the School of Medicine, see http://www.medschool.pitt.edu.
Contact: Taylor Andres
Mobile: 412-592-7406
E-mail: AndresTA@upmc.edu
Contact: Sarah Katz
Mobile: 412-312-1042
E-mail: KatzSB@upmc.edu
Journal
JAMA Surgery